Profile data is unavailable for this security.
About the company
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
- Revenue in USD (TTM)741.17m
- Net income in USD106.11m
- Incorporated1998
- Employees500.00
- LocationCorcept Therapeutics Inc101 REDWOOD SHORES PARKWAYREDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 688-8803
- Fax+1 (650) 327-3218
- Websitehttps://www.corcept.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals Inc | 366.10m | -81.16m | 2.63bn | 323.00 | -- | 7.85 | -- | 7.19 | -2.01 | -2.01 | 8.99 | 7.89 | 0.8039 | 7.39 | 7.19 | 1,133,437.00 | -17.82 | -33.35 | -22.30 | -37.21 | 93.26 | -- | -22.17 | -125.04 | 4.25 | -- | 0.1774 | -- | 948.62 | -- | 14.97 | -- | 106.47 | -- |
| Supernus Pharmaceuticals Inc | 681.54m | -19.12m | 2.83bn | 674.00 | -- | 2.69 | 42.70 | 4.15 | -0.3408 | -0.3408 | 12.09 | 18.38 | 0.4934 | 0.959 | 4.30 | 1,011,185.00 | -1.38 | 4.25 | -1.79 | 5.58 | 89.91 | 87.90 | -2.80 | 10.41 | 1.56 | -- | 0.00 | -- | 8.94 | 11.00 | 5,512.84 | -8.16 | -23.33 | -- |
| Apellis Pharmaceuticals Inc | 1.02bn | 44.99m | 2.85bn | 705.00 | 75.97 | 7.11 | 61.17 | 2.81 | 0.297 | 0.297 | 8.03 | 3.17 | 1.04 | 0.9298 | 3.25 | 1,441,698.00 | 4.59 | -61.31 | 6.04 | -76.53 | 88.85 | 86.49 | 4.43 | -157.26 | 3.10 | 2.51 | 0.5313 | -- | 97.02 | -- | 62.57 | -- | -24.96 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 2.89bn | 979.00 | -- | 6.33 | -- | 7.38 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Catalyst Pharmaceuticals Inc | 578.20m | 217.56m | 2.94bn | 181.00 | 13.95 | 3.20 | 11.51 | 5.08 | 1.71 | 1.71 | 4.55 | 7.47 | 0.6341 | 3.45 | 7.02 | 3,194,453.00 | 23.86 | 24.62 | 27.38 | 28.82 | 85.68 | 85.77 | 37.63 | 31.73 | 6.40 | -- | 0.00 | 0.00 | 23.49 | 36.89 | 129.50 | 38.75 | 95.70 | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 200.84m | 3.15bn | 600.00 | 16.26 | 1.73 | 13.69 | 2.84 | 4.03 | 4.03 | 22.30 | 37.95 | 0.3286 | 3.09 | 6.13 | 1,850,798.00 | 5.94 | 4.13 | 6.16 | 4.30 | 56.10 | 56.31 | 18.09 | 13.13 | 2.51 | 8.11 | 0.3574 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Arcutis Biotherapeutics Inc | 317.93m | -44.32m | 3.19bn | 342.00 | -- | 19.84 | -- | 10.04 | -0.3545 | -0.3545 | 2.49 | 1.31 | 0.7866 | 1.75 | 3.63 | 929,616.90 | -10.97 | -61.20 | -16.53 | -68.48 | 89.96 | -- | -13.94 | -406.29 | 3.28 | -2.61 | 0.407 | -- | 229.74 | -- | 46.58 | -- | 77.12 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 597.97m | 35.92m | 3.23bn | 315.00 | 94.96 | 6.00 | 86.28 | 5.40 | 0.4484 | 0.4484 | 7.81 | 7.10 | 0.9435 | 2.13 | 15.61 | 1,898,327.00 | 5.67 | -8.31 | 6.85 | -9.52 | 87.52 | -- | 6.01 | -17.33 | 3.51 | -- | 0.00 | -- | 56.60 | -- | -406.68 | -- | -38.71 | -- |
| Liquidia Corp | 69.22m | -121.85m | 3.62bn | 157.00 | -- | 163.62 | -- | 52.24 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 3.77bn | 68.00 | 92.25 | 3.97 | 45.57 | 15.02 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| ADMA Biologics Inc | 488.56m | 209.45m | 3.79bn | 677.00 | 18.81 | 8.81 | 17.45 | 7.77 | 0.8476 | 0.8476 | 1.98 | 1.81 | 1.02 | 1.20 | 5.20 | 721,652.90 | 43.67 | -2.99 | 48.83 | -3.39 | 54.71 | 34.09 | 42.87 | -4.56 | 3.65 | 26.62 | 0.1438 | -- | 65.15 | 70.79 | 800.00 | -- | 17.60 | -- |
| Corcept Therapeutics Inc | 741.17m | 106.11m | 4.04bn | 500.00 | 43.31 | 6.38 | 37.62 | 5.44 | 0.8858 | 0.8858 | 6.19 | 6.01 | 0.9219 | 1.31 | 11.46 | 1,482,344.00 | 13.20 | 20.07 | 16.21 | 23.01 | 98.19 | 98.53 | 14.32 | 24.89 | 3.07 | -- | 0.00 | 0.00 | 39.94 | 17.11 | 33.04 | 8.44 | 14.83 | -- |
| TG Therapeutics Inc | 531.90m | 447.47m | 4.41bn | 374.00 | 9.99 | 7.10 | 9.85 | 8.29 | 2.78 | 2.78 | 3.29 | 3.91 | 0.6603 | 0.6733 | 2.79 | 1,573,663.00 | 55.55 | -42.93 | 67.33 | -52.55 | 85.34 | -- | 84.13 | -142.45 | 2.89 | 3.77 | 0.2878 | -- | 40.80 | 364.59 | 84.52 | -- | -19.24 | -- |
| Amneal Pharmaceuticals Inc | 2.93bn | 5.90m | 4.64bn | 8.10k | 894.07 | -- | 15.58 | 1.58 | 0.0165 | 0.0165 | 9.17 | -0.3483 | 0.8313 | 3.07 | 3.59 | 362,340.60 | 1.63 | -2.12 | 2.32 | -2.68 | 36.76 | 35.94 | 1.96 | -3.47 | 1.42 | 1.47 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| Mirum Pharmaceuticals Inc | 471.79m | -41.42m | 5.08bn | 355.00 | -- | 17.26 | -- | 10.76 | -0.8613 | -0.8613 | 9.26 | 5.69 | 0.6494 | 4.15 | 5.37 | 1,465,199.00 | -5.70 | -29.54 | -7.04 | -34.57 | 79.92 | -- | -8.78 | -92.71 | 3.16 | -22.48 | 0.5144 | -- | 80.76 | -- | 46.18 | -- | 136.96 | -- |
Data as of Feb 06 2026. Currency figures normalised to Corcept Therapeutics Inc's reporting currency: US Dollar USD
45.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 10.93m | 10.39% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.77m | 8.34% |
| Ingalls & Snyder LLCas of 30 Sep 2025 | 7.70m | 7.32% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 6.09m | 5.79% |
| Parallel Advisors LLCas of 30 Sep 2025 | 3.87m | 3.68% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.97m | 2.82% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 2.14m | 2.04% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.93m | 1.84% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 1.80m | 1.71% |
| AQR Capital Management LLCas of 30 Sep 2025 | 1.51m | 1.43% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
